Fexofenadine, a histamine H 1 -receptor antagonist, is approved for the treatment of pruritus associated with atopic dermatitis. The effects of fexofenadine on scratching behaviour, and plasma levels of histamine and eotaxin were assessed in a new model of atopic dermatitis. Mice fed a diet low in Mg 2+ and Zn 2+ (special diet S) were compared with mice on a normal diet (N) or diet S plus fexofenadine HCl for weeks 0 -10 (S + F 0 -10 ), 0 -5 (S + F 0 -5 ) or 6 -10 (S + F 6 -10 ) (seven mice per group). Compared with group N, group S mice showed significantly greater scratching frequency, and plasma histamine and eotaxin concentrations; these three variables were significantly lower in group S + F 0 -10 than in group S. Scratching frequency increased when fexofenadine was discontinued. Fexofenadine significantly reduced mast cell and eosinophil numbers. Histamine may be important in the pathological changes seen in this model of atopic dermatitis, suggesting that it might aid future development of antihistamines for the treatment of atopic dermatitis.
Introduction
Atopic dermatitis (AD) is a chronic relapsing skin disease, often associated with elevated levels of immunoglobulin E (IgE) and a personal or family history of atopic disorders. Acute phases of the disease are characterized primarily by extreme pruritus, which in turn leads to excoriation. Excoriation further exacerbates the underlying inflammation, setting up an itch-scratch cycle that results in chronic lesions. 1, 2 The pathophysiology of AD is complex and has not yet been fully clarified. Several mouse models of human AD have been developed as a useful tool for investigation of the pathology underlying the disease and the development of new therapies. 3 -5 We have recently reported the development of a new mouse model (HR-ADf) of human AD. 6 HR-1 hairless mice fed a special diet containing approximately 50% lower Mg 2+ and Zn 2+ concentrations than a standard diet exhibit many of the clinical characteristics of AD, including dry skin, scratching behaviour, significant decreases in the water content of the H Akamatsu, M Makiura, N Yamamoto et al. Fexofenadine treatment in a mouse model of atopic dermatitis corneum, significant increases in transepidermal water loss and significant increases in blood IgE levels.
The H 1 -receptor antagonist fexofenadine is approved in Japan for the treatment of the pruritus associated with AD. In the present study, the effect of fexofenadine HCl 40 mg/kg per day on scratching behaviour -and hence pruritus -was examined in the HR-1 hairless mouse model. Plasma concentrations of histamine and eotaxin, and skin histopathology were also examined.
Materials and methods

STUDY ANIMALS
HR-1 hairless mice were obtained from Hoshino Laboratory Animals (Saitama, Japan). The committee for laboratory animals of Fujita Health University provided ethical approval for the study. All experiments were performed in accordance with the Fujita Health University guidelines for the management of laboratory animals.
FEED
The standard diet was mouse chow CRF-1 (Oriental Yeast Co. Ltd, Chiba, Japan). The special diet was based on the standard diet but was prepared with reduced concentrations of Mg 2+ and Zn 2+ . The concentrations of Mg 2+ and Zn 2+ in the standard diet were 0.25 g/100 g and 6 -7 mg/ 100 g, respectively, compared with 0.14 g/100 g of Mg 2+ and 3 -4 mg/100 g of Zn 2+ in the special diet. Fexofenadine was obtained from Aventis Pharma Ltd (Tokyo, Japan).
FEEDING REGIMEN
HR-1 hairless mice were kept in a specific pathogen-free environment. After weaning at 4 weeks of age, the mice were separated into five groups, each with a different feeding regimen: standard (normal) diet (N); special diet (S); special diet and from week 0 to week 10 fexofenadine HCl 40 mg/kg per day (S + F 0 -10 ); special diet and from week 0 to week 5 fexofenadine HCl 40 mg/kg per day (S + F 0 -5 ); and special diet and from week 6 to week 10 fexofenadine HCl 40 mg/kg per day (S + F 6 -10 ).
Approximately 4 -6 g per day of the normal or special diet was provided ad libitum. Fexofenadine was administered orally in a 0.5% aqueous suspension of sodium carboxymethylcellulose once daily. An equivalent volume of 0.5% aqueous sodium carboxymethylcellulose solution was similarly administered to mice that did not receive fexofenadine (groups N and S).
MEASUREMENT OF SCRATCHING FREQUENCY
Scratching behaviour was measured at weeks 3 -10 after initiation of the experimental feeding regimens. Mice were videotaped for 30 min and the frequency of scratching was counted retrospectively at sequential 5-min intervals. The cumulative frequency of scratching every 5 min was calculated.
Scratching behaviour was categorized into three patterns of behaviour: scratching the face, scalp, neck and back with the hind limbs; grooming the head with the fore and hind limbs; and licking the abdomen or back.
SKIN HISTOPATHOLOGY AND HAEMATOLOGY
Blood samples were collected at weeks 4, 6, 8 and 10, and skin biopsies were taken after the mice had been killed at the end of week 10.
Skin biopsy specimens were stained with haematoxylin and eosin to examine epidermal thickening and leucocyte infiltration. Eosinophil and mast cell infiltration was assessed by Hansel staining H Akamatsu, M Makiura, N Yamamoto et al. Fexofenadine treatment in a mouse model of atopic dermatitis and toluidine blue staining, respectively. Immunostaining was performed using a rabbit anti-mouse eotaxin polyclonal antibody (Chemicon International, Temecula, CA, USA). The numbers of eosinophils and mast cells were assessed by counting the cell number per field of view (× 400), using a microscope. The intensity of eotaxin immunostaining was scored by the following criteria: 0 = no staining; 1 = slight staining; 2 = moderate staining; 3 = marked staining; 4 = very strong staining.
Eotaxin and histamine levels were determined using the Analyza Mouse Eotaxin Immunoassay Kit (Techne Corp., Minneapolis, MN, USA) and the Histamine ELISA Kit (IBL: Immuno-Biological Laboratories Co., Ltd, Gunma, Japan), according to the manufacturer's instructions. Both test kits were based on modified enzyme-linked immunosorbent assay (ELISA) protocols.
STATISTICAL ANALYSIS
An analysis of variance (ANOVA) model was used to assess the statistical significance of differences among the five feeding groups.
Results are expressed as the mean ± SD of each group. P-values < 0.05 were considered statistically significant.
Results
Seven mice were allocated to each feeding group; all survived to the end of the study and were included in the analysis of results.
SCRATCHING FREQUENCY
The change in the mean frequency of the first of the three categories of scratching behaviour (scratching the face, scalp, neck and back with the hind limbs) in each feeding group over time is shown in Fig. 1 . The mice in group S consistently showed a significantly greater (P < 0.01) scratching frequency than FIGURE 1: Change in mean scratching frequency for each feeding group (n = 7 for each group) of mice over time. N, standard diet; S, special diet (Mg 2+ and Zn 2+ reduced to 50% of that of the standard diet); S + F 0 -10 , special diet and from week 0 (start of experimental feeding regimen) to week 10 fexofenadine HCl 40 mg/kg per day; S + F 0 -5 , special diet and from week 0 to week 5 fexofenadine HCl 40 mg/kg per day; S + F 6 -10 , special diet and from week 6 to week 10 fexofenadine HCl 40 mg/kg per day 
FIGURE 2:
Comparison of mean scratching frequency for each feeding group of mice at weeks 5 and 6. N, standard diet; S, special diet (Mg 2+ and Zn 2+ reduced to 50% of that of the standard diet); S + F 0 -10 , special diet and from week 0 (start of experimental feeding regimen) to week 10 fexofenadine HCl 40 mg/kg per day; S + F 0 -5 , special diet and from week 0 to week 5 fexofenadine HCl 40 mg/kg per day; S + F 6 -10 , special diet and from week 6 to week 10 fexofenadine HCl 40 mg/kg per day. Results are expressed as mean ± SD of each group (n = 7). *P < 0.05, **P < 0.01 H Akamatsu, M Makiura, N Yamamoto et al. Fexofenadine treatment in a mouse model of atopic dermatitis the mice in group N; scratching frequency in group S reached a peak at weeks 5 -6. No significant differences were seen between groups for the frequencies of the remaining two categories of scratching behaviour (grooming and licking; data not shown).
The mice in group S + F 0 -10 showed a significant decrease (P < 0.01) in scratching frequency compared with mice in group S. Mice in group S + F 0 -5 scratched more frequently (P < 0.05) once fexofenadine had been discontinued at week 5. In contrast, mice in the S + F 6 -10 group showed reduced scratching behaviour following the introduction of fexofenadine administration at week 6. The reduction in scratching behaviour between weeks 5 and 6 in group S + F 6 -10 was not significant. Figure 2 summarizes the changes in scratching behaviour between weeks 5 and 6.
SKIN HISTOPATHOLOGY
Haematoxylin-eosin staining showed thickening of the epidermis and marked infiltration of leucocytes into the dermis in skin biopsies from mice in group S compared with mice in group N. Biopsies from mice in group S + F 0 -10 showed reduced epidermal thickening and cellular infiltration compared with group S mice ( Fig. 3 ).
Toluidine blue staining showed significantly more (P < 0.01) mast cells in skin biopsies from group S mice than from mice in group N (54.4 ± 7.5 and 27.3 ± 7.3 [mean ± SD] cells per field of view, respectively). The number of mast cells in skin biopsies from mice in the S + F 0 -10 group was significantly lower (P < 0.05) than that seen in group S mice (37.3 ± 9.3 versus 54.4 ± 7.5 [mean ± SD] cells per field of view, respectively) ( Fig. 4) . With Hansel staining, the number of eosinophils seen in skin biopsies from mice in the S + F 0 -10 group was similar to that seen in biopsies from mice in group N (19.3 ± 4.3 and 15.1 ± 4.1 [mean ± SD] cells per field of view, respectively). In contrast, the number of eosinophils in skin biopsies from group S mice (29.5 ± 6.0 [mean ± SD] cells per field of view) was significantly higher (P < 0.01) than from group N mice. Eosinophil numbers were significantly lower (P < 0.05) in biopsies from mice in the S + F 0 -10 group than from mice in group S (Fig. 5) .
The scores for intensity of eotaxin immunostaining were 0.6 ± 0.5, 3.0 ± 0.9 and : Immunostaining for eotaxin of skin biopsies from mice fed a standard diet (N), a special diet alone (S; Mg 2+ and Zn 2+ reduced to 50% of that of the standard diet) and a special diet together with fexofenadine HCl 40 mg/kg per day from week 0 (start of experimental feeding regimen) to week 10 (S + F 0 -10 ) N S S + F 0 -10 1.3 ± 0.5 (mean ± SD) for biopsies from mice in groups N, S and S + F 0 -10 , respectively. Biopsies from group S mice showed a significantly higher (P < 0.01) intensity of staining compared with biopsies from group N mice. Staining intensity in biopsies from mice in the S + F 0 -10 group was significantly lower than that in biopsies from group S (P < 0.01) ( Fig. 6) . Figure 7 shows the mean plasma histamine levels for mice in groups N, S and S + F 0 -10 at weeks 4, 6, 8 and 10. Mice in group S were consistently found to have a higher plasma histamine level than mice in group N (P < 0.01); plasma histamine reached a peak at week 6 in all groups. Mice in group Figure 8 shows the mean plasma eotaxin levels of mice in groups N, S and S + F 0 -10 at weeks 4, 6, 8 and 10. Mice in group S were consistently found to have a higher plasma eotaxin level than mice in group N (P < 0.01 at weeks 4, 6 and 10; P < 0.05 at week 8); plasma eotaxin reached a peak at week 6 in groups N and S. In contrast, mice in group S + F 0 -10 had significantly lower (P < 0.01) plasma eotaxin levels than mice in group S throughout the study period.
HAEMATOLOGICAL FINDINGS
Discussion
Fexofenadine significantly reduced (P < 0.01) the frequency of scratching, and plasma levels of histamine and eotaxin in the HR-1 hairless mouse model of AD, HR-ADf. Administration of fexofenadine also partially attenuated a number of pathological changes seen in the dermis of mice fed the special diet, suggesting that histamine plays an important role in the pathology of scratching in this mouse model.
Animal models of disease are very important tools in the development of new therapeutics. The recent development of several mouse models of human AD may lead to a greatly enhanced understanding of the pathological mechanisms underlying this disease. This, in turn, will lead to the development of more effective treatments for AD.
Fexofenadine is an H 1 -antihistamine agent that has been shown to be effective in the treatment of the pruritus associated with AD. 7 Fexofenadine directly abrogates the action of histamine on nerve cells as well as preventing the release of chemical mediators from mast cells, and suppresses vascular endothelial cell adhesion and eosinophil chemotaxis. 8 We measured the effect of fexofenadine on pruritus in the HR-ADf mouse model using the frequency of scratching behaviour as an evaluation index. Mice in the group fed the special diet (group S) consistently showed a high frequency of scratching, indicating a high degree of pruritus. The significant reduction (P < 0.01) in scratching frequency in mice in the group treated with fexofenadine for 10 weeks (group S + F 0 -10 ) compared with mice in group S indicates that fexofenadine was effective in relieving pruritus in this mouse model. The decrease in scratching frequency in group S + F 6 -10 mice following fexofenadine administration at week 6, together with the significant increase (P < 0.05) in scratching frequency in the group in which fexofenadine was withdrawn after 5 weeks of treatment (group S + F 0 -5 ) supports this observation and suggests that the pruritus experienced by HR-ADf mice is mediated by a mechanism similar to that in patients with AD.
The mice in the group on the special diet (group S) had significantly higher (P < 0.01) plasma histamine levels than the control group (group N). Similarly, increased numbers of mast cells were found in biopsies from group S mice compared with mice in the control group (group N) (P < 0.01). Increased scratching frequency was associated with increased plasma histamine levels. In contrast, mice receiving fexofenadine for 10 weeks showed significant reductions in plasma histamine levels (P < 0.01) and mast cell numbers (P < 0.05), concomitant with a significant reduction (P < 0.01) in scratching frequency compared with group S mice. Mastcell-derived histamine has been shown to cause pruritus by binding to the H 1 -receptors found on peripheral neurons. 9 associated with AD by preventing this binding event. 7, 8 This further suggests that histamine derived from mast cells is an important causative factor of the pruritus in this mouse model (which is similar to the pruritus associated with AD in humans).
The number of peripheral blood eosinophils is increased in patients with AD; furthermore, the observed increase correlates with the clinical severity of the disease. 10, 11 Eosinophils are thought to play an important role in the formation of the skin lesions commonly seen in AD. Skin lesions are caused by interleukin (IL)-5-or eotaxin-mediated eosinophilic infiltration into the skin, followed by eosinophil degranulation and subsequent release of cytotoxic proteins, including major basic protein or eosinophilic cationic protein. 12 It has been shown recently that eosinophils express high-affinity IgE receptors on their cell surface 13 and that eosinophils produce cytokines, including IL-4 or IL-5, 14 suggesting that these mediators may play an important role in the formation of skin lesions. Additionally, eosinophil-derived factors have been shown to be involved in pruritus. 15 The secretion of eotaxin is largely induced by IL-4 from mesenchymal cells, such as skin fibroblasts. 16 It has recently been shown in vitro, however, that histamine can also induce eotaxin secretion from fibroblasts and mediates this effect via the H 1 -receptor. 17 The same study showed that eotaxin induction was suppressed by epinastine (an H 1 -antihistamine).
We have recently observed higher levels of IL-4 and IL-5 (which are involved in eotaxin expression) in the dermis of mice fed the special diet used in the present work; the levels of these two cytokines were reduced on administration of fexofenadine (H Akamatsu, M Makiura, N Yamamoto, A Yagami, Y Shimizu and K Matsunaga; data not shown).
Mice in group S showed significantly greater numbers of dermal eosinophils (P < 0.01) and higher plasma eotaxin levels (P < 0.01 at weeks 4, 6 and 10; P < 0.05 at week 8) than mice in the control group (group N). Furthermore, skin biopsy sections from mice in group S were more densely stained for dermal eotaxin than those from mice in the control group (group N) (P < 0.01). Mice on the special diet that received fexofenadine for 10 weeks (group S + F 0 -10 ) showed significant decreases in eosinophil numbers (P < 0.05) as well as reduced plasma eotaxin levels (P < 0.01) compared with group S mice. Similarly, skin biopsies from mice in group S + F 0 -10 showed an attenuation (P < 0.01) of the dense immunostaining of dermal eotaxin seen in samples from group S mice. These observations suggest that fexofenadine suppresses the infiltration of eosinophils into the skin by suppressing either eosinophil adhesion to vascular endothelial cells or the chemotaxis of eosinophils. In addition, fexofenadine may prevent histaminemediated eotaxin secretion from skin fibroblasts in a manner similar to that reported for epinastine. Fexofenadine may further suppress eosinophil infiltration by impairing the release of cytokines IL-4 and IL-5 from mast cells.
In conclusion, there is strong evidence that many of the pathological changes observed in this new mouse model of AD, HR-ADf, are mediated by histamine derived from mast cells. We found that fexofenadine, an H 1 -receptor antagonist, relieved many of these changes in a manner similar to that observed in patients with AD. 18 HR-1 hairless mice fed the Mg 2+ -and Zn 2+ -deficient diet may provide a useful mouse model for the study of human AD. Furthermore, the HR-ADf mouse may serve as a valuable model in the development of new antihistamine agents.
